Literature DB >> 12646952

Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood.

F Fernández-Avilés1, A Urbano-Ispizua, M Aymerich, D Colomer, M Rovira, C Martínez, E Nadal, C Talarn, E Carreras, E Montserrat.   

Abstract

We used multiplex amplification of nine microsatellite sequences (PCR-STR) to analyse chimerism in pure populations of T cells and neutrophils from peripheral blood from 40 patients submitted to an allogeneic transplant, 22 having received a T-cell depleted (TCD) peripheral blood graft by means of CD34(+) selection (allo-PBT/CD34(+)), and 18, an unmodified graft (allo-SCT; 13 allogeneic bone marrow transplants and five allo-PBT). T-cell mixed chimerism (TcMC) was observed in 16 of the 22 (72.3%) patients receiving an allo-PBT/CD34(+), but in only one of the 18 (5.5%) patients receiving an allo-SCT (P=0.0001). TcMC was transient (n=6), stable (n=7), and associated with poor haematopoietic engraftment (n=4). All patients with TcMC who developed graft failure had more than 30% of host T cells. Myeloid MC (MyMC) was observed in four (19%) allo-PBT/CD34(+) patients and in three (17%) allo-SCT patients (P=NS). Five out of seven (71%) patients with MyMC relapsed, all of them diagnosed with myeloid malignancies, as compared with two of the 20 (10%) patients with complete donor chimerism (P&<0.0001). In conclusion, TcMC appears in a significant number of allo-PBT/CD34(+) patients and may be associated with poor engraftment when the percentage of host T cells is >30%; likewise, MyMC appears in a small percentage of recipients of both allo-PBT/CD34(+) and allo-SCT patients, and is associated with leukaemia relapse in myeloid malignancies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646952     DOI: 10.1038/sj.leu.2402854

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.

Authors:  Robert A Sokolic; Thomas R Bauer; Yu-Chen Gu; Mehreen Hai; Laura M Tuschong; Tanya Burkholder; Lyn Colenda; John Bacher; Matthew F Starost; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

2.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

3.  Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.

Authors:  Federico Moscardó; Jaime Sanz; Leonor Senent; Susana Cantero; Javier de la Rubia; Pau Montesinos; Dolores Planelles; Ignacio Lorenzo; Jose Cervera; Javier Palau; Miguel A Sanz; Guillermo F Sanz
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

4.  Hematopoietic chimerism monitoring based on STRs: quantitative platform performance on sequential samples.

Authors:  Don Kristt; Moshe Israeli; Ronit Narinski; Hagit Or; I Yaniv; Jerry Stein; Tirza Klein
Journal:  J Biomol Tech       Date:  2005-12

5.  Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Ri-Young Goh; Sung-Hyun Kim; Jin-Yeong Han
Journal:  Korean J Hematol       Date:  2011-03-15

6.  Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms.

Authors:  Paula Aguirre-Ruiz; Beñat Ariceta; María Cruz Viguria; María Teresa Zudaire; Zuriñe Blasco-Iturri; Patricia Arnedo; Almudena Aguilera-Diaz; Axier Jauregui; Amagoia Mañú; Felipe Prosper; María Carmen Mateos; Marta Fernández-Mercado; María José Larráyoz; Margarita Redondo; María José Calasanz; Iria Vázquez; Eva Bandrés
Journal:  J Clin Med       Date:  2020-11-25       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.